



6 March 2026

## Dispatch of General Meeting Documents

Argent BioPharma provides the following documents regarding a General Meeting of shareholders being held at 10:00AM (AWST) on Wednesday, 8 April 2026, at Suite 1, 295 Rokeby Road, Subiaco, WA 6008.

- Notice and Access Letter
- Notice of Meeting
- Sample Proxy Form

-ENDS-

Authorised for release by the board of directors, for further information please contact:

**Argent BioPharma**  
Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma**  
Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma Ltd. (ASX: RGT)** is a clinical-stage biopharmaceutical company developing nano-engineered medicines that restore balance between the nervous and immune systems. Its lead candidates, CannEpi<sup>®</sup> and CimetrA<sup>®</sup>, target drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, respectively. The Company's proprietary delivery platforms are designed to improve penetration across the blood-brain and alveolar-capillary barriers, enabling differentiated efficacy and supporting composition-of-matter protection. With EU-GMP manufacturing, advancing late-stage clinical programs, and a unified Neuro-Immune Modulatory platform, Argent BioPharma is building a high-impact pipeline with a clear focus on urgent unmet needs in CNS and systemic inflammation.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma





**Argent BioPharma Ltd**  
ABN 30 116 800 269

## Need assistance?



**Phone:**  
1300 850 505 (within Australia)  
+61 3 9415 4000 (outside Australia)



**Online:**  
[www.investorcentre.com/contact](http://www.investorcentre.com/contact)

RGT

MR SAM SAMPLE  
FLAT 123  
123 SAMPLE STREET  
THE SAMPLE HILL  
SAMPLE ESTATE  
SAMPLEVILLE VIC 3030

## Argent BioPharma Ltd General Meeting

The Argent BioPharma Ltd General Meeting will be held on Wednesday, 8 April 2026 at 10:00am (AWST). You are encouraged to participate in the meeting using the following options:



### MAKE YOUR VOTE COUNT

To lodge a proxy, access the Notice of Meeting and other meeting documentation visit [www.investorvote.com.au](http://www.investorvote.com.au) and use the below information:



**Control Number: 188611**  
**SRN/HIN:**  
**PIN:**

For Intermediary Online subscribers (custodians) go to [www.intermediaryonline.com](http://www.intermediaryonline.com)

For your proxy appointment to be effective it must be received by 10:00am (AWST) on Monday, 6 April 2026.



### ATTENDING THE MEETING IN PERSON

The meeting will be held at:  
Suite 1, 295 Rokeby Road, Subiaco, WA 6008

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.

---

**ARGENT BIOPHARMA LTD**  
**ACN 116 800 269**  
**NOTICE OF GENERAL MEETING**

---

Notice is given that the Meeting will be held at:

**TIME:** 10:00AM (AWST)  
**DATE:** 8 April 2026  
**PLACE:** Suite 1, 295 Rokeby Road  
Subiaco WA 6008

*The business of the Meeting affects your shareholding and your vote is important.*

*This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.*

*The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 5:00PM (AWST) on 6 April 2026.*

---

## **BUSINESS OF THE MEETING**

---

### **AGENDA**

---

#### **1. RESOLUTION 1 – APPROVAL TO ISSUE SHARES – CANNPAL ACQUISITION**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*“That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue up to 20,000,000 Shares to AusCann Group Holdings Ltd (or its nominee(s)) on the terms and conditions set out in the Explanatory Statement.”*

---

#### **2. RESOLUTION 2 - APPROVAL TO ISSUE SHARES – NEUVIS OPTION**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*“That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue up to that number of Shares that, when multiplied by the deemed issue price, equals \$2,000,000, to AusCann Group Holdings Ltd (or its nominee(s)) on the terms and conditions set out in the Explanatory Statement.”*

---

#### **3. RESOLUTION 3 – APPROVAL TO ISSUE SHARES TO DANIEL ROBINSON**

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

*“That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 500,000 Shares to Daniel Robinson (or his nominee(s)) on the terms and conditions set out in the Explanatory Statement.”*

---

#### **4. RESOLUTION 4 – APPROVAL TO ISSUE SHARES TO GARY HERMON**

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

*“That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 500,000 Shares to Gary Hermon (or his nominee(s)) on the terms and conditions set out in the Explanatory Statement.”*

---

#### **5. RESOLUTION 5 – APPROVAL TO ISSUE SHARES TO ROBY ZOMER**

To consider and, if thought fit, to pass, the following resolution as an **ordinary resolution**:

*“That, for the purposes of section 208 of the Corporations Act, Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 711,267 Shares to Roby Zomer (or his nominee(s)) on the terms and conditions set out in the Explanatory Statement.”*

---

#### **6. RESOLUTION 6 – RATIFICATION OF PRIOR ISSUE OF SHARES UNDER LISTING RULE 7.1 – GREEN IGUANA PTY LTD**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*“That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 616,000 Shares to Green Iguana Pty Ltd on the terms and conditions set out in the Explanatory Statement.”*

---

**7. RESOLUTION 7 – APPROVAL TO ISSUE SHARES TO GREEN IGUANA PTY LTD**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*“That, for the purposes of Listing Rule 7.1 and for all other purposes, approval is given for the Company to issue up to 206,000 Shares to Green Iguana Pty Ltd (or its nominee(s)) on the terms and conditions set out in the Explanatory Statement.”*

---

**8. RESOLUTION 8 – APPROVAL TO ISSUE PERFORMANCE RIGHTS TO ROBY ZOMER**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*“That, for the purposes of Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue 17,000,000 Performance Rights to Roby Zomer (or their nominee(s)) on the terms and conditions set out in the Explanatory Statement.”*

---

**Dated: 6 March 2026**

## Voting Prohibition Statement:

<b>Resolution 3 – Approval to issue Shares to Daniel Robinson</b>	<p>In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of a related party of the Company to whom the Resolution would permit a financial benefit to be given, or an associate of such a related party (<b>Resolution 3 Excluded Party</b>). However, the above prohibition does not apply if the vote is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the Resolution and it is not cast on behalf of a Resolution 3 Excluded Party.</p> <p>In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if:</p> <ul style="list-style-type: none"><li>(a) the proxy is either:<ul style="list-style-type: none"><li>(i) a member of the Key Management Personnel; or</li><li>(ii) a Closely Related Party of such a member; and</li></ul></li><li>(b) the appointment does not specify the way the proxy is to vote on this Resolution.</li></ul> <p>Provided the Chair is not a Resolution 3 Excluded Party, the above prohibition does not apply if:</p> <ul style="list-style-type: none"><li>(a) the proxy is the Chair; and</li><li>(b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.</li></ul>
<b>Resolution 4 – Approval to issue Shares to Gary Hermon</b>	<p>In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of a related party of the Company to whom the Resolution would permit a financial benefit to be given, or an associate of such a related party (<b>Resolution 4 Excluded Party</b>). However, the above prohibition does not apply if the vote is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the Resolution and it is not cast on behalf of a Resolution 4 Excluded Party.</p> <p>In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if:</p> <ul style="list-style-type: none"><li>(a) the proxy is either:<ul style="list-style-type: none"><li>(i) a member of the Key Management Personnel; or</li><li>(ii) a Closely Related Party of such a member; and</li></ul></li><li>(b) the appointment does not specify the way the proxy is to vote on this Resolution.</li></ul> <p>Provided the Chair is not a Resolution 4 Excluded Party, the above prohibition does not apply if:</p> <ul style="list-style-type: none"><li>(a) the proxy is the Chair; and</li><li>(b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.</li></ul>
<b>Resolution 5 – Approval to issue Shares to Roby Zomer</b>	<p>In accordance with section 224 of the Corporations Act, a vote on this Resolution must not be cast (in any capacity) by or on behalf of a related party of the Company to whom the Resolution would permit a financial benefit to be given, or an associate of such a related party (<b>Resolution 5 Excluded Party</b>). However, the above prohibition does not apply if the vote is cast by a person as proxy appointed by writing that specifies how the proxy is to vote on the Resolution and it is not cast on behalf of a Resolution 5 Excluded Party.</p> <p>In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if:</p> <ul style="list-style-type: none"><li>(a) the proxy is either:<ul style="list-style-type: none"><li>(i) a member of the Key Management Personnel; or</li><li>(ii) a Closely Related Party of such a member; and</li></ul></li><li>(b) the appointment does not specify the way the proxy is to vote on this Resolution.</li></ul> <p>Provided the Chair is not a Resolution 5 Excluded Party, the above prohibition does not apply if:</p> <ul style="list-style-type: none"><li>(a) the proxy is the Chair; and</li><li>(b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.</li></ul>
<b>Resolution 8 – Approval to issue Performance Rights to Roby Zomer</b>	<p>A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if:</p> <ul style="list-style-type: none"><li>(a) the proxy is either:<ul style="list-style-type: none"><li>(i) a member of the Key Management Personnel; or</li><li>(ii) a Closely Related Party of such a member; and</li></ul></li><li>(b) the appointment does not specify the way the proxy is to vote on this Resolution.</li></ul> <p>However, the above prohibition does not apply if:</p> <ul style="list-style-type: none"><li>(a) the proxy is the Chair; and</li><li>(b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel.</li></ul>

## Voting Exclusion Statements

In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolution set out below by or on behalf of the following persons:

<b>Resolution 1 – Approval to issue Shares – CannPal Acquisition</b>	AusCann Group Holdings Ltd or any other person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons).
<b>Resolution 2 – Approval to issue Shares – Neuvis Option</b>	AusCann Group Holdings Ltd or any other person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons).
<b>Resolution 3 – Approval to issue shares to Daniel Robinson</b>	Daniel Robinson (or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person or those persons.
<b>Resolution 4 – Approval to issue shares to Gary Hermon</b>	Gary Hermon (or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person or those persons.
<b>Resolution 5 – Approval to issue shares to Roby Zomer</b>	Roby Zomer (or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person or those persons.
<b>Resolution 6 – Ratification of prior issue of Shares under Listing Rule 7.1 - Green Iguana Pty Ltd</b>	Green Iguana Pty Ltd or any other person who participated in the issue or an associate of that person or those persons.
<b>Resolution 7 – Approval to issue Shares to Green Iguana Pty Ltd</b>	Green Iguana Pty Ltd or any other person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons).
<b>Resolution 8 – Approval to issue Performance Rights to Roby Zomer</b>	Roby Zomer (or their nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- (a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or
- (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
  - (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

## **Voting by proxy**

---

To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form.

In accordance with section 249L of the Corporations Act, Shareholders are advised that:

- each Shareholder has a right to appoint a proxy;
- the proxy need not be a Shareholder of the Company; and
- a Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the Shareholder appoints two proxies and the appointment does not specify the proportion or number of the member's votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes.

Shareholders and their proxies should be aware that:

- if proxy holders vote, they must cast all directed proxies as directed; and
- any directed proxies which are not voted will automatically default to the Chair, who must vote the proxies as directed.

## **Voting in person**

---

To vote in person, attend the Meeting at the time, date and place set out above.

***Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company Secretary on +61 8 6555 2950.***

---

## EXPLANATORY STATEMENT

---

This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions.

---

### 1. BACKGROUND TO RESOLUTIONS 1 AND 2

#### 1.1 General

As announced on 14 January 2026, the Company has entered into an agreement (**Acquisition Agreement**) with AusCann Group Holdings Ltd (ACN 008 095 207) (**AC8**) to acquire:

- (a) 100% of AC8's shareholding in CannPal Animal Therapeutics Limited (48%) (**CannPal Acquisition**); and
- (b) an option to acquire 100% of AC8'S right, title and interest in the Neuvis IP (**Neuvis Option**),

(together, the **AusCann Transactions**).

The key terms of the AusCann Transactions are set out below.

CANNPAL ACQUISITION	
<b>Consideration</b>	The consideration payable for the CannPal Acquisition is 20,000,000 Shares at a deemed issue price of \$0.10 per Share, subject to receipt of shareholder approval (the subject of Resolution 1).  All Shares issued as consideration will be subject to a voluntary escrow period of 3 months from completion of the CannPal Acquisition.
<b>Conditions Precedent</b>	Completion of the CannPal Acquisition is conditional upon the passing of Resolution 1.
NEUVIS OPTION	
<b>Consideration</b>	The consideration payable upon exercise of the Neuvis Option is \$2,000,000 worth of Shares at a deemed issue price equal to the 20-day VWAP prior to the exercise of the Option, subject to receipt of shareholder approval (the subject of Resolution 2).
<b>Conditions Precedent</b>	As a condition of Neuvis Option completion, the parties must enter into a production royalty agreement in favour of AC8 (or its nominee) in respect of net sales of products that are manufactured or supplied using, or materially derived from, the Neuvis IP, on terms to be agreed acting reasonably and in good faith.

The agreements otherwise contain customary terms and conditions.

Following completion of the CannPal Acquisition, Mr Andrew Chapman will join the Board of the Company as an Executive Director, bringing extensive experience in capital markets and the biotechnology sector in Australia and internationally. Concurrently, Mr Roby Zomer will transition to the role of Non-Executive Chairman, supporting the Company's next phase of development, including its U.S. national exchange listing strategy and the integration and advancement of the newly acquired assets and advancing potential USA partnership and commercial opportunities.

---

### 2. RESOLUTION 1 – APPROVAL TO ISSUE SHARES – CANNPAL ACQUISITION

As set out in Section 1.1, this Resolution seeks Shareholder approval for the purposes of Listing Rule 7.1 for the issue of 20,000,000 Shares in consideration for CannPal Acquisition.

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

The proposed issue falls within exception 17 of Listing Rule 7.2 which excludes from the restrictions in Listing Rules 7.1 and 7.1A an agreement to issue equity securities that is conditional on the holders of its ordinary securities approving the issue under Listing Rule 7.1 before the issue is made. The proposed issue therefore requires the approval of Shareholders under Listing Rule 7.1.

## 2.1 Technical information required by Listing Rule 14.1A

If this Resolution is passed, the Company will be able to proceed with the issue. In addition, the issue will be excluded from the calculation of the number of equity securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If this Resolution is not passed, the Company will be unable to proceed with the issue, which is a condition precedent to completion. In that event, if the Company wishes to continue with the acquisition, it will be required to renegotiate the terms of the acquisition with AC8.

## 2.2 Technical information required by Listing Rule 7.3

REQUIRED INFORMATION	DETAILS
<b>Names of persons to whom Securities will be issued or the basis on which those persons were or will be identified/selected</b>	AusCann Group Holdings Ltd (ACN 008 095 207) (or its nominee(s)).
<b>Number of Securities and class to be issued</b>	20,000,000 Shares.
<b>Terms of Securities</b>	The Shares will be fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
<b>Date(s) on or by which the Securities will be issued</b>	The Company will issue the Shares on completion of the CannPal Acquisition. In any event, the Company will not issue any Shares later than three months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
<b>Price or other consideration the Company will receive for the Securities</b>	The Shares will be issued in consideration for the CannPal Acquisition.
<b>Purpose of the issue, including the intended use of any funds raised by the issue</b>	The purpose of the issue is to satisfy the Company's obligations under the Acquisition Agreement.
<b>Summary of material terms of agreement to issue</b>	The Shares are being issued under the Acquisition Agreement, a summary of the material terms of which is set out in Section 1.1.
<b>Voting exclusion statement</b>	A voting exclusion statement applies to this Resolution.

## 3. RESOLUTION 2 – APPROVAL TO ISSUE SHARES – NEUVIS OPTION

As set out in Section 1.1, this Resolution seeks Shareholder approval for the purposes of Listing Rule 7.1 for the issue of up to \$2,000,000 worth of Shares, at a deemed issue price equal to the 20-day volume-weighted average price (**VWAP**) prior to the exercise of the Option (**Deemed Issue Price**).

A summary of Listing Rule 7.1 is set out in Section 2.1 above.

The proposed issue falls within exception 17 of Listing Rule 7.2 which excludes from the restrictions in Listing Rules 7.1 and 7.1A an agreement to issue equity securities that is conditional on the holders of its ordinary securities approving the issue under Listing Rule 7.1 before the issue is made. The proposed issue therefore requires the approval of Shareholders under Listing Rule 7.1.

### 3.1 Technical information required by Listing Rule 14.1A

If this Resolution is passed, the Company will be able to proceed with the issue. In addition, the issue will be excluded from the calculation of the number of equity securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If this Resolution is not passed, the Company will be unable to proceed with the issue, which is a condition precedent to completion). In that event, if the Company wishes to continue with the acquisition, it will be required to renegotiate the terms of the acquisition with AC8.

### 3.2 Technical information required by Listing Rule 7.3

REQUIRED INFORMATION	DETAILS
<b>Names of persons to whom Securities will be issued or the basis on which those persons were or will be identified/selected</b>	AusCann Group Holdings Ltd (ACN 008 095 207) (or its nominee(s)).
<b>Number of Securities and class to be issued</b>	The maximum number of Shares to be issued is \$2,000,000 divided by the Deemed Issue Price. As an example, if the Deemed Issue Price were equal to the closing price of Shares as at 9 February 2026, being \$0.054, a total of 37,037,037 Shares would be issued.
<b>Terms of Securities</b>	The Shares will be fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
<b>Date(s) on or by which the Securities will be issued</b>	Subject to exercise of the Neuvis Option, the Company expects to issue the Shares on completion of the acquisition of the Neuvis IP. In any event, the Company will not issue any Shares later than three months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
<b>Price or other consideration the Company will receive for the Securities</b>	The Shares will be issued in consideration for the acquisition of the Neuvis IP.
<b>Purpose of the issue, including the intended use of any funds raised by the issue</b>	The purpose of the issue is to satisfy the Company's obligations under the Acquisition Agreement.
<b>Summary of material terms of agreement to issue</b>	The Shares are being issued under the Acquisition Agreement, a summary of the material terms of which is set out in Section 1.1.
<b>Voting exclusion statement</b>	A voting exclusion statement applies to this Resolution.

---

## 4. RESOLUTIONS 3 TO 5 – APPROVAL TO ISSUE SHARES TO DIRECTORS

### 4.1 General

These Resolutions seek Shareholder approval for the purposes of Chapter 2E of the Corporations Act and Listing Rule 10.11 for the issue of up to an aggregate of 1,711,267 Shares to Directors (or their nominee(s)) on the terms and conditions set out below. The proposed issue forms part of the Directors' remuneration arrangements. Further details of the Shares proposed to be issued are set out in the table below.

RECIPIENT	QUANTUM	RESOLUTION
Daniel Robinson	500,000	3
Gary Hermon	500,000	4
Roby Zomer	711,267	5

### 4.2 Director Recommendation

Each Director has a material personal interest in the outcome of these Resolutions on the basis that all of the Directors (or their nominee(s)) are to be issued Shares should these Resolutions be passed. For this reason, the Directors do not believe that it is appropriate to make a recommendation on these Resolutions.

### 4.3 Chapter 2E of the Corporations Act

Chapter 2E of the Corporations Act requires that for a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must:

- (a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and
- (b) give the benefit within 15 months following such approval,

unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

The issue constitutes giving a financial benefit and each of the proposed recipients is a related party of the Company by virtue of being a Director.

As Shares are proposed to be issued to all of the Directors, the Directors are unable to form a quorum to consider whether one of the exceptions set out in sections 210 to 216 of the Corporations Act applies to the issue. Accordingly, Shareholder approval for the issue is sought in accordance with Chapter 2E of the Corporations Act.

### 4.4 Listing Rule 10.11

Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue equity securities to:

- 10.11.1 a related party;
- 10.11.2 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (30%+) holder in the company;
- 10.11.3 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;
- 10.11.4 an associate of a person referred to in Listing Rules 10.11.1 to 10.11.3; or
- 10.11.5 a person whose relationship with the company or a person referred to in Listing Rules 10.11.1 to 10.11.4 is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains the approval of its shareholders.

The issue falls within Listing Rule 10.11.1 and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of Shareholders under Listing Rule 10.11.

#### 4.5 Technical information required by Listing Rule 14.1A

If these Resolutions are passed, the Company will be able to proceed with the issues within one month after the date of the Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules). As approval pursuant to Listing Rule 7.1 is not required for the issues (because approval is being obtained under Listing Rule 10.11), the issues will not use up any of the Company's 15% annual placement capacity.

If these Resolutions are not passed, the Company will not be able to proceed with the issues. At the date of this Notice, the Board has not determined any alternative remuneration or incentive arrangements for the relevant parties. The Board may consider alternative arrangements (including cash-based remuneration and/or alternative equity incentives) having regard to the Company's circumstances and the requirements of the ASX Listing Rules and the Corporations Act.

#### 4.6 Technical Information required by Listing Rule 10.13 and section 219 of the Corporations Act

REQUIRED INFORMATION	DETAILS
<b>Name of the persons to whom Securities will be issued</b>	The proposed recipients of the Shares are set out in Section 4.1 above.
<b>Categorisation under Listing Rule 10.11</b>	Each of the proposed recipients falls within the category set out in Listing Rule 10.11.1 as they are a related party of the Company by virtue of being a Director.  Any nominee(s) of the proposed recipients who receive Shares may constitute 'associates' for the purposes of Listing Rule 10.11.4.
<b>Number of Securities and class to be issued</b>	The maximum number of Shares to be issued (being the nature of the financial benefit proposed to be given) is 1,711,267 which will be allocated are set out in the table included at Section 4.1 above.
<b>Terms of Securities</b>	The Shares will be fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
<b>Date(s) on or by which the Securities will be issued</b>	The Company expects to issue the Shares within 5 Business Days of the Meeting. In any event, the Company will not issue any Shares later than one month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
<b>Price or other consideration the Company will receive for the Securities</b>	The Shares are being issue at nil issue price.
<b>Purpose of the issue, including the intended use of any funds raised by the issue</b>	The purpose of the issue is to provide a performance linked incentive component in the remuneration package for each Director, to motivate and reward their performance as Director and to provide cost effective remuneration to each Director, enabling the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to each Director.

REQUIRED INFORMATION	DETAILS																								
<p><b>Consideration of type and quantum of Security to be issued</b></p>	<p>The number of Shares to be issued has been determined based upon a consideration of:</p> <ul style="list-style-type: none"> <li>(a) current market standards and/or practices of other ASX listed companies of a similar size and stage of development to the Company;</li> <li>(b) the remuneration of the proposed recipients; and</li> <li>(c) incentives to attract and ensure continuity of service/retain the service of the proposed recipients who have appropriate knowledge and expertise, while maintaining the Company's cash reserves.</li> </ul> <p>It is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Shares on the terms proposed.</p>																								
<p><b>Remuneration</b></p>	<p>The total remuneration package for each of the proposed recipients for the previous financial year and the proposed total remuneration package for the current financial year are set out below:</p> <table border="1" data-bbox="639 891 1369 1131"> <thead> <tr> <th>RELATED PARTY</th> <th>CURRENT FINANCIAL YEAR ENDING 30 JUNE 2026</th> <th>PREVIOUS FINANCIAL YEAR ENDED 30 JUNE 2025</th> </tr> </thead> <tbody> <tr> <td>Daniel Robinson</td> <td>\$44,000<sup>1</sup></td> <td>\$44,000<sup>1</sup></td> </tr> <tr> <td>Gary Hermon</td> <td>\$44,000<sup>1</sup></td> <td>\$11,484<sup>1</sup></td> </tr> <tr> <td>Roby Zomer</td> <td>\$337,476<sup>1</sup></td> <td>\$2,435,524<sup>2</sup></td> </tr> </tbody> </table> <p><b>Notes:</b></p> <ol style="list-style-type: none"> <li>Comprising Directors' fees/salary.</li> <li>Comprising Directors' fees/salary of \$315,524 and share-based payments of \$2,120,000.</li> </ol>	RELATED PARTY	CURRENT FINANCIAL YEAR ENDING 30 JUNE 2026	PREVIOUS FINANCIAL YEAR ENDED 30 JUNE 2025	Daniel Robinson	\$44,000 <sup>1</sup>	\$44,000 <sup>1</sup>	Gary Hermon	\$44,000 <sup>1</sup>	\$11,484 <sup>1</sup>	Roby Zomer	\$337,476 <sup>1</sup>	\$2,435,524 <sup>2</sup>												
RELATED PARTY	CURRENT FINANCIAL YEAR ENDING 30 JUNE 2026	PREVIOUS FINANCIAL YEAR ENDED 30 JUNE 2025																							
Daniel Robinson	\$44,000 <sup>1</sup>	\$44,000 <sup>1</sup>																							
Gary Hermon	\$44,000 <sup>1</sup>	\$11,484 <sup>1</sup>																							
Roby Zomer	\$337,476 <sup>1</sup>	\$2,435,524 <sup>2</sup>																							
<p><b>Valuation</b></p>	<p>Based on the closing price of Shares as at 9 February 2026, being \$0.054, the value of the Shares proposed to be issued is set out in the table below:</p> <table border="1" data-bbox="639 1384 1369 1568"> <thead> <tr> <th>RECIPIENT</th> <th>SHARES</th> <th>VALUE</th> </tr> </thead> <tbody> <tr> <td>Daniel Robinson</td> <td>500,000</td> <td>\$27,000</td> </tr> <tr> <td>Gary Hermon</td> <td>500,000</td> <td>\$27,000</td> </tr> <tr> <td>Roby Zomer</td> <td>711,267</td> <td>\$38,408</td> </tr> </tbody> </table>	RECIPIENT	SHARES	VALUE	Daniel Robinson	500,000	\$27,000	Gary Hermon	500,000	\$27,000	Roby Zomer	711,267	\$38,408												
RECIPIENT	SHARES	VALUE																							
Daniel Robinson	500,000	\$27,000																							
Gary Hermon	500,000	\$27,000																							
Roby Zomer	711,267	\$38,408																							
<p><b>Summary of material terms of agreement to issue</b></p>	<p>The Shares are not being issued under an agreement.</p>																								
<p><b>Interest in Securities</b></p>	<p>The relevant interests of the proposed recipients in Shares as at the date of this Notice and following completion of the issue are set out below:</p> <p><b>As at the date of this Notice</b></p> <table border="1" data-bbox="639 1841 1369 2101"> <thead> <tr> <th>RELATED PARTY</th> <th>SHARES<sup>1</sup></th> <th>OPTIONS</th> <th>PERFORMANCE RIGHTS</th> <th>UNDILUTED</th> <th>FULLY DILUTED</th> </tr> </thead> <tbody> <tr> <td>Daniel Robinson</td> <td>Nil</td> <td>120,000<sup>2</sup></td> <td>Nil</td> <td>0%</td> <td>0.07%</td> </tr> <tr> <td>Gary Hermon</td> <td>Nil</td> <td>Nil</td> <td>Nil</td> <td>0%</td> <td>0%</td> </tr> <tr> <td>Roby Zomer</td> <td>5,292,321</td> <td>Nil</td> <td>Nil</td> <td>6.27%</td> <td>3.31%</td> </tr> </tbody> </table>	RELATED PARTY	SHARES <sup>1</sup>	OPTIONS	PERFORMANCE RIGHTS	UNDILUTED	FULLY DILUTED	Daniel Robinson	Nil	120,000 <sup>2</sup>	Nil	0%	0.07%	Gary Hermon	Nil	Nil	Nil	0%	0%	Roby Zomer	5,292,321	Nil	Nil	6.27%	3.31%
RELATED PARTY	SHARES <sup>1</sup>	OPTIONS	PERFORMANCE RIGHTS	UNDILUTED	FULLY DILUTED																				
Daniel Robinson	Nil	120,000 <sup>2</sup>	Nil	0%	0.07%																				
Gary Hermon	Nil	Nil	Nil	0%	0%																				
Roby Zomer	5,292,321	Nil	Nil	6.27%	3.31%																				

REQUIRED INFORMATION	DETAILS																
	<p><b>Post issue</b></p> <table border="1"> <thead> <tr> <th style="background-color: #002060; color: white;">RELATED PARTY</th> <th style="background-color: #002060; color: white;">SHARES<sup>1</sup></th> <th style="background-color: #002060; color: white;">OPTIONS</th> <th style="background-color: #002060; color: white;">PERFORMANCE RIGHTS</th> </tr> </thead> <tbody> <tr> <td>Daniel Robinson</td> <td>500,000</td> <td>120,000</td> <td>Nil</td> </tr> <tr> <td>Gary Hermon</td> <td>500,000</td> <td>Nil</td> <td>Nil</td> </tr> <tr> <td>Roby Zomer</td> <td>6,003,588</td> <td>Nil</td> <td>Nil</td> </tr> </tbody> </table> <p><b>Notes:</b></p> <ol style="list-style-type: none"> <li>Fully paid ordinary shares in the capital of the Company (ASX: RGT).</li> <li>Unquoted Options exercisable at \$0.42 on or before 28 March 2027.</li> </ol>	RELATED PARTY	SHARES <sup>1</sup>	OPTIONS	PERFORMANCE RIGHTS	Daniel Robinson	500,000	120,000	Nil	Gary Hermon	500,000	Nil	Nil	Roby Zomer	6,003,588	Nil	Nil
RELATED PARTY	SHARES <sup>1</sup>	OPTIONS	PERFORMANCE RIGHTS														
Daniel Robinson	500,000	120,000	Nil														
Gary Hermon	500,000	Nil	Nil														
Roby Zomer	6,003,588	Nil	Nil														
<b>Dilution</b>	<p>If Resolutions 3 to 5 are passed, a total of 1,711,267 Shares would be issued. This will increase the number of Shares on issue from 86,942,317 (being the total number of Shares on issue as at the date of this Notice) to 88,653,584 (assuming that no Shares are issued and no other convertible securities vest or are exercised) with the effect that the shareholding of existing Shareholders would be diluted by an aggregate of 1.93%, comprising 0.56% by Daniel Robinson, 0.56% by Gary Hermon, and 0.80% by Roby Zomer.</p>																
<b>Trading history</b>	<p>The trading history of the Shares on ASX in the 12 months before the date of this Notice is set out below:</p> <table border="1"> <thead> <tr> <th style="background-color: #002060; color: white;"></th> <th style="background-color: #002060; color: white;">PRICE</th> <th style="background-color: #002060; color: white;">DATE</th> </tr> </thead> <tbody> <tr> <td>Highest</td> <td>\$0.320</td> <td>19 August 2025</td> </tr> <tr> <td>Lowest</td> <td>\$0.052</td> <td>6 February 2026</td> </tr> <tr> <td>Last</td> <td>\$0.051</td> <td>20 February 2026</td> </tr> </tbody> </table>		PRICE	DATE	Highest	\$0.320	19 August 2025	Lowest	\$0.052	6 February 2026	Last	\$0.051	20 February 2026				
	PRICE	DATE															
Highest	\$0.320	19 August 2025															
Lowest	\$0.052	6 February 2026															
Last	\$0.051	20 February 2026															
<b>Other information</b>	<p>The Board is not aware of any other information that is reasonably required by Shareholders to allow them to decide whether it is in the best interests of the Company to pass these Resolutions.</p>																
<b>Voting exclusion statements</b>	<p>Voting exclusion statements apply to these Resolutions.</p>																
<b>Voting prohibition statements</b>	<p>Voting prohibition statements apply to these Resolutions.</p>																

## 5. RESOLUTION 6 – RATIFICATION OF PRIOR ISSUE OF SHARES UNDER LISTING RULE 7.1 – GREEN IGUANA PTY LTD

### 5.1 General

This Resolution seeks Shareholder ratification for the purposes of Listing Rule 7.4 for the issue of 616,000 Shares to Green Iguana Pty Ltd in lieu of cash payment for corporate advisory services provided to the Company.

### 5.2 Listing Rule 7.1

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

The issue does not fit within any of the exceptions set out in Listing Rule 7.2 and, as it has not yet been approved by Shareholders, it effectively uses up part of the 15% limit in Listing Rule 7.1, reducing the Company's capacity to issue further equity securities without Shareholder approval under Listing Rule 7.1 for the 12 month period following the date of the issue.

### 5.3 Listing Rule 7.4

Listing Rule 7.4 allows the shareholders of a listed company to approve an issue of equity securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under Listing Rule 7.1 and so does not reduce the company's capacity to issue further equity securities without shareholder approval under that rule.

The Company wishes to retain as much flexibility as possible to issue additional equity securities in the future without having to obtain Shareholder approval for such issues under Listing Rule 7.1. Accordingly, the Company is seeking Shareholder ratification pursuant to Listing Rule 7.4 for the issue.

### 5.4 Technical information required by Listing Rule 14.1A

If this Resolution is passed, the issue will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of the issue.

If this Resolution is not passed, the issue will be included in calculating the Company's 15% limit in Listing Rule 7.1, effectively decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the date of the issue.

### 5.5 Technical information required by Listing Rules 7.4 and 7.5

REQUIRED INFORMATION	DETAILS
<b>Names of persons to whom Securities were issued or the basis on which those persons were identified/selected</b>	Green Iguana Pty Ltd.
<b>Number and class of Securities issued</b>	616,000 Shares.
<b>Terms of Securities</b>	The Shares were fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
<b>Date(s) on or by which the Securities were issued</b>	9 December 2025.
<b>Price or other consideration the Company received for the Securities</b>	Issued as consideration for corporate advisory services provided to the Company.
<b>Purpose of the issue, including the intended use of any funds raised by the issue</b>	Issued as consideration for corporate advisory services provided to the Company.
<b>Summary of material terms of agreement to issue</b>	The Shares were issued to Green Iguana Pty Ltd under a corporate advisory agreement. Under the corporate advisory agreement, Green Iguana has agreed to provide Argent BioPharma with corporate advice relating to strategy and planning in respect to strategic fund raisings, equity capital markets in Australia, United States and the United Kingdom. The Company agreed to issue 616,000

REQUIRED INFORMATION	DETAILS
	Shares to Green Iguana Pty Ltd as part consideration for these services. The agreement otherwise contains provisions considered standard for an agreement of this nature.
<b>Voting Exclusion Statement</b>	A voting exclusion statement applies to this Resolution.
<b>Compliance</b>	The issue did not breach Listing Rule 7.1.

## 6. RESOLUTION 7 – APPROVAL TO ISSUE SHARES TO GREEN IGUANA PTY LTD

### 6.1 General

This Resolution seeks Shareholder approval for the purposes of Listing Rule 7.1 for the issue of up to 206,000 Shares to Green Iguana Pty Ltd (or its nominee) in consideration for corporate advisory services provided to the Company.

A summary of Listing Rule 7.1 is set out in Section 5.2 above.

The proposed issue does not fit within any of the exceptions set out in Listing Rule 7.2. While the issue does not exceed the 15% limit in Listing Rule 7.1 and can therefore be made without breaching that rule, the Company wishes to retain as much flexibility as possible to issue additional equity securities in the future without having to obtain Shareholder approval under Listing Rule 7.1. Accordingly, the Company is seeking Shareholder approval pursuant to Listing Rule 7.1 so that it does not use up any of its 15% placement capacity under Listing Rule 7.1.

### 6.2 Technical information required by Listing Rule 14.1A

If this Resolution is passed, the Company will be able to proceed with the issue. In addition, the issue will be excluded from the calculation of the number of equity securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If this Resolution is not passed, the Company will not be able to proceed with the issue and may be required to re-negotiate fees payable to Green Iguana Pty Ltd.

### 6.3 Technical information required by Listing Rule 7.3

REQUIRED INFORMATION	DETAILS
<b>Names of persons to whom Securities will be issued or the basis on which those persons were or will be identified/selected</b>	Green Iguana Pty Ltd (or its nominee).
<b>Number of Securities and class to be issued</b>	206,000 Shares will be issued.
<b>Terms of Securities</b>	The Shares will be fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
<b>Date(s) on or by which the Securities will be issued</b>	The Company expects to issue the Shares within 5 Business Days of the Meeting. In any event, the Company will not issue any Shares later than three months after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
<b>Price or other consideration the Company will receive for the Securities</b>	The Shares will be issued at a in consideration for corporate advisory services provided.

REQUIRED INFORMATION	DETAILS
<b>Purpose of the issue, including the intended use of any funds raised by the issue</b>	The Shares will be issued at a in consideration for corporate advisory services provided.
<b>Summary of material terms of agreement to issue</b>	The Shares were issued to Green Iguana Pty Ltd under a corporate advisory agreement. Under the corporate advisory agreement, Green Iguana has agreed to provide Argent BioPharma with corporate advice relating to strategy and planning in respect to strategic fund raisings, equity capital markets in Australia, United States and the United Kingdom. The Company agreed to issue 206,000 Shares to Green Iguana Pty Ltd as part consideration for these services. The agreement otherwise contains provisions considered standard for an agreement of this nature.
<b>Voting exclusion statement</b>	A voting exclusion statement applies to this Resolution.

## **7. RESOLUTION 8 – APPROVAL TO ISSUE PERFORMANCE RIGHTS TO ROBY ZOMER**

### **7.1 General**

This Resolution seeks Shareholder approval for the purposes of Listing Rule 10.11 for the issue of 17,000,000 Performance Rights to Roby Zomer (or his nominee(s)) on the terms and conditions set out below.

Further details in respect of the Performance Rights proposed to be issued are set out in Schedule 1.

### **7.2 Chapter 2E of the Corporations Act**

A summary of Chapter 2E of the Corporations Act is set out in Section 4.3 above.

The issue constitutes giving a financial benefit and Roby Zomer is a related party of the Company by virtue of being a Director.

The Directors (other than Roby Zomer who has a material personal interest in the Resolution) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue because the agreement to issue the Performance Rights, reached as part of the remuneration package for Roby Zomer, is considered reasonable remuneration in the circumstances and was negotiated on an arm's length basis.

### **7.3 Listing Rule 10.11**

A summary of Listing Rule 10.11 is set out in Section 4.4 above.

The issue falls within Listing Rule 10.11.1 and does not fall within any of the exceptions in Listing Rule 10.12. It therefore requires the approval of Shareholders under Listing Rule 10.11.

### **7.4 Technical information required by Listing Rule 14.1A**

If this Resolution is passed, the Company will be able to proceed with the issue within one month after the date of the Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules). As approval pursuant to Listing Rule 7.1 is not required for the issue (because approval is being obtained under Listing Rule 10.11), the issue will not use up any of the Company's 15% annual placement capacity.

If this Resolution is not passed, the Company will not be able to proceed with the issue and the Company may consider alternative means to remunerate Roby Zomer.

## 7.5 Technical Information required by Listing Rule 10.13

REQUIRED INFORMATION	DETAILS
<b>Name of the person to whom Securities will be issued</b>	Roby Zomer (or his nominee/s)
<b>Categorisation under Listing Rule 10.11</b>	The recipient falls within the category set out in Listing Rule 10.11.1 as they are a related party of the Company by virtue of being a Director.  Any nominee(s) of the recipient who receive Securities may constitute 'associates' for the purposes of Listing Rule 10.11.4.
<b>Number of Securities and class to be issued</b>	17,000,000 Performance Rights will be issued.
<b>Terms of Securities</b>	The Performance Rights will be issued on the terms and conditions set out in Schedule 1.
<b>Date(s) on or by which the Securities will be issued</b>	The Company expects to issue the Performance Rights within 5 Business Days of the Meeting. In any event, the Company will not issue any Performance Rights later than one month after the date of the Meeting (or such later date to the extent permitted by any ASX waiver or modification of the Listing Rules).
<b>Price or other consideration the Company will receive for the Securities</b>	The Performance Rights will be issued at a nil issue price.
<b>Purpose of the issue, including the intended use of any funds raised by the issue</b>	The purpose of the issue is to provide a performance linked incentive component in the remuneration package for Roby Zomer to motivate and reward their performance as a Director and to provide cost effective remuneration to Roby Zomer, enabling the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Roby Zomer.
<b>Remuneration package</b>	The current total remuneration package for Roby Zomer (excluding the ordinary shares proposed to be issued within this notice) is \$337,476, comprising of directors' fees/salary. If the Performance Rights are issued, the total remuneration package of Roby Zomer will increase by \$918,000 to \$1,255,476, being the value of the Performance Rights (based on the Black Scholes methodology).
<b>Summary of material terms of agreement to issue</b>	The Performance Rights are not being issued under any agreement.
<b>Voting exclusion statement</b>	A voting exclusion statement applies to this Resolution.
<b>Voting prohibition statement</b>	A voting prohibition statement applies to this Resolution.

---

## GLOSSARY

---

**\$** means Australian dollars.

**ASIC** means the Australian Securities & Investments Commission.

**ASX** means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

**AusCann Transactions** has the meaning given in Section 1.1.

**Board** means the current board of directors of the Company.

**Business Day** means Monday to Friday inclusive, except New Year's Day, Good Friday, Easter Monday, Christmas Day, Boxing Day, and any other day that ASX declares is not a business day.

**Chair** means the chair of the Meeting.

**Company** means Argent BioPharma Ltd (ACN 116 800 269).

**Constitution** means the Company's constitution.

**Corporations Act** means the *Corporations Act 2001* (Cth).

**Directors** means the current directors of the Company.

**Explanatory Statement** means the explanatory statement accompanying the Notice.

**Listing Rules** means the Listing Rules of ASX.

**Meeting** means the meeting convened by the Notice.

**Neuvis IP** means all intellectual property and related rights owned by AC8 and used or intended to be used in connection with the Neuvis drug delivery capsule and associated SEDDS-based formulation and encapsulation platform, including all rights in: inventions, formulations, know-how, data, specifications, processes, documentation, trade secrets, regulatory dossiers (if any), brand/trade marks (registered and unregistered), designs, domain names, software/source code (if any), and all applications and registrations for the foregoing.

**Notice** means this notice of meeting including the Explanatory Statement and the Proxy Form.

**Option** means an option to acquire a Share.

**Proxy Form** means the proxy form accompanying the Notice.

**Resolutions** means the resolutions set out in the Notice, or any one of them, as the context requires.

**Section** means a section of the Explanatory Statement.

**Security** means a Share or Option (as applicable).

**Share** means a fully paid ordinary share in the capital of the Company.

**Shareholder** means a registered holder of a Share.

**WST** means Western Standard Time as observed in Perth, Western Australia.


## SCHEDULE 1 – TERMS AND CONDITIONS OF PERFORMANCE RIGHTS


1.	<b>Entitlement</b>	Each Performance Right entitles the holder to subscribe for one Share upon conversion of the Performance Right.						
2.	<b>Consideration</b>	The Performance Rights will be issued for nil consideration and no consideration will be payable upon the conversion of the Performance Rights into Shares.						
3.	<b>Vesting Conditions</b>	<p>The Performance Rights will only vest if both of the following vesting conditions are satisfied:</p> <table border="1" data-bbox="531 499 1388 902"> <thead> <tr> <th data-bbox="531 499 647 551">CLASS</th> <th data-bbox="647 499 1388 551">VESTING CONDITION</th> </tr> </thead> <tbody> <tr> <td data-bbox="531 551 647 633">A</td> <td data-bbox="647 551 1388 633">Settlement of the CannPal Acquisition pursuant to the Acquisition Agreement.</td> </tr> <tr> <td data-bbox="531 633 647 902">B</td> <td data-bbox="647 633 1388 902">The Company is admitted to the official list of either NASDAQ or the New York Stock Exchange (whether directly or indirectly, including via a reverse merger, backdoor listing or other transaction involving a listed shell) (an <b>Uplisting</b>) and the Company completes, either concurrently with the Uplisting or within 12 months after it, one or more capital raisings generating gross proceeds of at least US\$5,000,000 in aggregate.</td> </tr> </tbody> </table> <p>each, a <b>Vesting Condition</b>.</p>	CLASS	VESTING CONDITION	A	Settlement of the CannPal Acquisition pursuant to the Acquisition Agreement.	B	The Company is admitted to the official list of either NASDAQ or the New York Stock Exchange (whether directly or indirectly, including via a reverse merger, backdoor listing or other transaction involving a listed shell) (an <b>Uplisting</b> ) and the Company completes, either concurrently with the Uplisting or within 12 months after it, one or more capital raisings generating gross proceeds of at least US\$5,000,000 in aggregate.
CLASS	VESTING CONDITION							
A	Settlement of the CannPal Acquisition pursuant to the Acquisition Agreement.							
B	The Company is admitted to the official list of either NASDAQ or the New York Stock Exchange (whether directly or indirectly, including via a reverse merger, backdoor listing or other transaction involving a listed shell) (an <b>Uplisting</b> ) and the Company completes, either concurrently with the Uplisting or within 12 months after it, one or more capital raisings generating gross proceeds of at least US\$5,000,000 in aggregate.							
4.	<b>Expiry Date</b>	<p>The Performance Rights whether vested or unvested, will otherwise expire on the earlier to occur of (<b>Expiry Date</b>):</p> <p>(a) the holder ceasing to be an officer (and employee, if applicable) or an employee of the Company (where they are not an officer at the time of issue), as applicable, unless otherwise determined by the Board at its absolute discretion; and</p> <p>(b) 5:00 pm (WST) on the date which is 5 years from the date of issue.</p> <p>For the avoidance of doubt, any unconverted Performance Rights will automatically lapse on the Expiry Date.</p>						
5.	<b>Notice of vesting</b>	The Company shall notify the holder in writing when the relevant Vesting Condition has been satisfied.						
6.	<b>Quotation of Performance Rights</b>	The Performance Rights will not be quoted on ASX.						
7.	<b>Conversion</b>	Subject to paragraph 15, upon vesting, each Performance Right will, at the election of the holder, convert into one Share.						
8.	<b>Timing of issue of Shares on conversion</b>	<p>Within five Business Days of conversion of the Performance Rights, the Company will:</p> <p>(a) issue the number of Shares required under these terms and conditions in respect of the number of Performance Rights converted;</p> <p>(b) if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and</p> <p>(c) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the</p>						

		<p>exercise of the Performance Rights.</p> <p>If a notice delivered under 8(b) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.</p>
9.	<b>Shares issued on exercise</b>	Shares issued on exercise of the Performance Rights rank equally with the then issued shares of the Company.
10.	<b>Participation in new issues</b>	There are no participation rights or entitlements inherent in the Performance Rights and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Performance Rights without converting the Performance Rights.
11.	<b>Adjustment for bonus issues of Shares</b>	If the Company makes a bonus issue of Shares or other securities to the Company's existing shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment no changes will be made to the Performance Rights.
12.	<b>Reorganisation</b>	If at any time the issued capital of the Company is reorganised (including consolidation, subdivision, reduction or return), all rights of a holder will be changed in a manner consistent with the applicable ASX Listing Rules and the Corporations Act at the time of reorganisation.
13.	<b>Dividend and voting rights</b>	The Performance Rights do not confer on the holder an entitlement to vote (except as otherwise required by law) or receive dividends.
14.	<b>Transferability</b>	The Performance Rights are not transferable.
15.	<b>Deferral of conversion if resulting in a prohibited acquisition of Shares</b>	<p>If the conversion of a Performance Right under paragraph 7 would result in any person being in contravention of section 606(1) of the Corporations Act (<b>General Prohibition</b>) then the conversion of that Performance Right shall be deferred until such later time or times that the conversion would not result in a contravention of the General Prohibition. In assessing whether a conversion of a Performance Right would result in a contravention of the General Prohibition:</p> <p>(a) holders may give written notification to the Company if they consider that the conversion of a Performance Right may result in the contravention of the General Prohibition. The absence of such written notification from the holder will entitle the Company to assume the conversion of a Performance Right will not result in any person being in contravention of the General Prohibition; and</p> <p>(b) the Company may (but is not obliged to) by written notice to a holder request a holder to provide the written notice referred to in paragraph 15(a) within 7 days if the Company considers that the conversion of a Performance Right may result in a contravention of the General Prohibition. The absence of such written notification from the holder will entitle the Company to assume the conversion of a Performance Right will not result in any person being in contravention of the General Prohibition.</p>
16.	<b>No rights to return of capital</b>	A Performance Right does not entitle the holder to a return of capital, whether in a winding up, upon a reduction of capital or otherwise.
17.	<b>Rights on winding up</b>	A Performance Right does not entitle the holder to participate in the surplus profits or assets of the Company upon winding up.

<b>18.</b>	<b>ASX Listing Rule compliance</b>	The Board reserves the right to amend any term of the Performance Rights to ensure compliance with the ASX Listing Rules.
<b>19.</b>	<b>No other rights</b>	A Performance Right gives the holder no rights other than those expressly provided by these terms and conditions and those provided at law where such rights at law cannot be excluded by these terms.

## Need assistance?

 **Phone:**  
1300 850 505 (within Australia)  
+61 3 9415 4000 (outside Australia)

 **Online:**  
[www.investorcentre.com/contact](http://www.investorcentre.com/contact)



## YOUR VOTE IS IMPORTANT

For your proxy appointment to be effective it must be received by **10:00am (AWST) on Monday, 6 April 2026.**

# Proxy Form

## How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

### APPOINTMENT OF PROXY

**Voting 100% of your holding:** Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote or abstain as they choose (to the extent permitted by law). If you mark more than one box on an item your vote will be invalid on that item.

**Voting a portion of your holding:** Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%.

**Appointing a second proxy:** You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

**A proxy need not be a securityholder of the Company.**

### SIGNING INSTRUCTIONS FOR POSTAL FORMS

**Individual:** Where the holding is in one name, the securityholder must sign.

**Joint Holding:** Where the holding is in more than one name, all of the securityholders should sign.

**Power of Attorney:** If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

**Companies:** Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held. Delete titles as applicable.

### PARTICIPATING IN THE MEETING

#### Corporate Representative

If a representative of a corporate securityholder or proxy is to participate in the meeting you will need to provide the appropriate "Appointment of Corporate Representative". A form may be obtained from Computershare or online at [www.investorcentre.com/au](http://www.investorcentre.com/au) and select "Printable Forms".

## Lodge your Proxy Form:

### Online:

Lodge your vote online at [www.investorvote.com.au](http://www.investorvote.com.au) using your secure access information or use your mobile device to scan the personalised QR code.

Your secure access information is

**Control Number: 188611**

**SRN/HIN:**

For Intermediary Online subscribers (custodians) go to [www.intermediaryonline.com](http://www.intermediaryonline.com)

### By Mail:

Computershare Investor Services Pty Limited  
GPO Box 242  
Melbourne VIC 3001  
Australia

### By Fax:

1800 783 447 within Australia or  
+61 3 9473 2555 outside Australia



**PLEASE NOTE:** For security reasons it is important that you keep your SRN/HIN confidential.

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.

**Change of address.** If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with 'X') should advise your broker of any changes.

# Proxy Form

Please mark  to indicate your directions

## Step 1 Appoint a Proxy to Vote on Your Behalf

I/We being a member/s of Argent BioPharma Ltd hereby appoint

the Chair of the Meeting **OR**

**PLEASE NOTE:** Leave this box blank if you have selected the Chair of the Meeting. Do not insert your own name(s).

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chair of the Meeting, as my/our proxy to act generally at the meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, and to the extent permitted by law, as the proxy sees fit) at the General Meeting of Argent BioPharma Ltd to be held at Suite 1, 295 Rokeby Road, Subiaco, WA 6008 on Wednesday, 8 April 2026 at 10:00am (AWST) and at any adjournment or postponement of that meeting.

**Chair authorised to exercise undirected proxies on remuneration related resolutions:** Where I/we have appointed the Chair of the Meeting as my/our proxy (or the Chair becomes my/our proxy by default), I/we expressly authorise the Chair to exercise my/our proxy on Resolutions 3, 4, 5 and 8 (except where I/we have indicated a different voting intention in step 2) even though Resolutions 3, 4, 5 and 8 are connected directly or indirectly with the remuneration of a member of key management personnel, which includes the Chair.

**Important Note:** If the Chair of the Meeting is (or becomes) your proxy you can direct the Chair to vote for or against or abstain from voting on Resolutions 3, 4, 5 and 8 by marking the appropriate box in step 2.

## Step 2 Items of Business

**PLEASE NOTE:** If you mark the **Abstain** box for an item, you are directing your proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.

	For	Against	Abstain
Resolution 1 Approval to issue Shares - CannPal Acquisition	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 2 Approval to issue Shares - Neuvis Option	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 3 Approval to issue Shares to Daniel Robinson	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 4 Approval to issue Shares to Gary Hermon	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 5 Approval to issue Shares to Roby Zomer	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 6 Ratification of prior issue of Shares under Listing Rule 7.1 - Green Iguana Pty Ltd	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 7 Approval to issue Shares to Green Iguana Pty Ltd	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Resolution 8 Approval to issue Performance Rights to Roby Zomer	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

The Chair of the Meeting intends to vote undirected proxies in favour of each item of business. In exceptional circumstances, the Chair of the Meeting may change his/her voting intention on any resolution, in which case an ASX announcement will be made.

## Step 3 Signature of Securityholder(s) *This section must be completed.*

Individual or Securityholder 1  Securityholder 2  Securityholder 3  / /  
 Sole Director & Sole Company Secretary Director Director/Company Secretary Date

**Update your communication details** (Optional)

Mobile Number  Email Address  By providing your email address, you consent to receive future Notice of Meeting & Proxy communications electronically